Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ASPEN AEROGELS INC (ASPN)
|
Add to portfolio |
|
|
|
| Price: |
$18.71
| | Metrics |
| OS: |
70.2
|
M
| |
-17
|
% ROE
|
| Market cap: |
$1.31
|
B
| |
-19
|
% ROIC
|
|
Net cash:
|
$25.1
|
M
| |
$0.36
|
per share
|
|
EV:
|
$1.29
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($80.9)
|
M
| |
|
|
| EPS |
($1.46)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 180.4 | 121.6 | 100.3 | 139.4 | 104.4 | 111.6 | 117.7 | 122.5 |
| Revenue growth | 48.3% | 21.3% | -28.1% | 33.6% | -6.5% | -5.2% | -3.9% | 19.6% |
| Cost of goods sold | 175.4 | 111.7 | 85.7 | 113.1 | 91.7 | 93.0 | 94.4 | 97.9 |
| Gross profit | 5.0 | 9.9 | 14.6 | 26.3 | 12.7 | 18.7 | 23.3 | 24.6 |
| Gross margin | 2.8% | 8.2% | 14.6% | 18.9% | 12.1% | 16.7% | 19.8% | 20.1% |
| Sales and marketing | 28.8 | 16.6 | 11.8 | 15.6 | 13.8 | 12.6 | 11.8 | 10.6 |
| Research and development | | | | 8.4 | 6.3 | 6.2 | 5.3 | 5.3 |
| General and administrative | | | | 16.5 | 19.1 | 19.0 | 17.4 | 15.1 |
| EBIT | -86.2 | -33.6 | -22.0 | -14.2 | -26.6 | -19.1 | -11.2 | -6.2 |
| EBIT margin | -47.8% | -27.6% | -22.0% | -10.2% | -25.5% | -17.1% | -9.5% | -5.1% |
| Pre-tax income | -82.7 | -37.1 | -21.8 | -14.6 | -34.4 | -19.3 | -12.0 | -6.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -82.7 | -37.1 | -21.8 | -14.6 | -34.4 | -19.3 | -12.0 | -6.4 |
| Net margin | -45.9% | -30.5% | -21.7% | -10.5% | -33.0% | -17.3% | -10.2% | -5.2% |
| |
| Diluted EPS | ($2.10) | ($1.22) | ($0.83) | ($0.60) | ($1.45) | ($0.83) | ($0.52) | ($0.28) |
| Shares outstanding (diluted) | 39.4 | 30.4 | 26.4 | 24.1 | 23.7 | 23.4 | 23.1 | 23.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|